Truist Financial analyst Asthika Goonewardene maintained a Hold rating on Instil Bio (TIL – Research Report) on September 5. The company’s shares closed yesterday at $0.43.
According to TipRanks, Goonewardene is an analyst with an average return of -17.3% and a 28.87% success rate. Goonewardene covers the Healthcare sector, focusing on stocks such as Mersana Therapeutics, Genmab, and Compugen.
Instil Bio has an analyst consensus of Moderate Buy, with a price target consensus of $3.50.
See Insiders’ Hot Stocks on TipRanks >>
TIL market cap is currently $57.9M and has a P/E ratio of -0.31.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Instil Bio Inc is a clinical-stage cell therapy company. It is developing tumor infiltrating lymphocytes for the treatment of cancer.
Read More on TIL:
